the BioNTech laboratory wants to launch a first drug in 2026

The German laboratory’s objective is to obtain authorizations for ten treatments by 2030.

The German laboratory BioNTech, which developed one of the innovative vaccines against Covid-19, declared on Wednesday March 20 that it was aiming to commercialize a first treatment against cancer in 2026, in particular using messenger RNA technology ( mRNA). “The company plans to continue developing its projects with a view to its first launch in oncology planned for 2026”announced BioNTech in a press release on the occasion of the publication of its annual results.

BioNTech is currently working on several therapies against different cancers (melanoma, prostate, head and neck, ovarian, lung, colorectal), immunotherapies and vaccines, currently in clinical trials. In total, the laboratory hopes to obtain authorizations for ten of these treatments by 2030, the press release adds.

Moderna aims for treatment approval in 2025

After selling millions of doses of its anti-Covid vaccine developed with the American giant Pfizer, BioNTech reinvested its profits in cancer research, the initial specialty of this laboratory created in 2008 by two oncology researchers. Messenger RNA technology offers new perspectives for the development of innovative therapies against cancer which are the subject of intense competition between several players in the pharmaceutical world.

The American laboratory Moderna, one of BioNTech’s rivals, hopes that its therapeutic vaccine against skin cancer, currently undergoing trials, will be approved by 2025.

The therapies these companies are working on aim not to fight cancer cells directly, but to strengthen patients’ immune systems so that they fight cancer.